Shaanxi Kanghui Pharmaceutical Co., Ltd.

SHSE:603139 Stock Report

Market Cap: CN¥1.6b

Shaanxi Kanghui Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shaanxi Kanghui Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Insufficient Growth At Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Hampers Share Price

Sep 30
Insufficient Growth At Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Hampers Share Price

Market Cool On Shaanxi Kanghui Pharmaceutical Co., Ltd.'s (SHSE:603139) Revenues Pushing Shares 28% Lower

Jun 09
Market Cool On Shaanxi Kanghui Pharmaceutical Co., Ltd.'s (SHSE:603139) Revenues Pushing Shares 28% Lower

Little Excitement Around Shaanxi Kanghui Pharmaceutical Co., Ltd.'s (SHSE:603139) Revenues

Feb 27
Little Excitement Around Shaanxi Kanghui Pharmaceutical Co., Ltd.'s (SHSE:603139) Revenues

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shaanxi Kanghui Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SHSE:603139 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024605-74-65-8N/A
6/30/2024669-47-61-7N/A
3/31/2024677-33-105-56N/A
12/31/2023673-26-145-72N/A
9/30/2023589-70-153-96N/A
6/30/2023518-64-176-79N/A
3/31/2023498-64-10718N/A
12/31/2022492-63-8850N/A
9/30/202248331-7971N/A
6/30/202247235-13567N/A
3/31/202246436-18850N/A
12/31/202144336-2837N/A
9/30/202145726-30574N/A
6/30/202145233-227106N/A
3/31/202142836-193114N/A
12/31/202041434-17294N/A
9/30/202041940-65138N/A
6/30/20204224010152N/A
3/31/202042739-17119N/A
12/31/20194314326108N/A
9/30/20194325556104N/A
6/30/201939952-1036N/A
3/31/2019388566471N/A
12/31/2018376565763N/A
9/30/201838360-12-7N/A
6/30/201837966N/A7N/A
3/31/201838364N/A25N/A
12/31/201736763N/A44N/A
9/30/201738466N/A81N/A
6/30/201738665N/A59N/A
3/31/201738565N/A70N/A
12/31/201638265N/A72N/A
12/31/201538062N/A29N/A
12/31/201437663N/A23N/A
12/31/201332856N/A39N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 603139's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 603139's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 603139's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 603139's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 603139's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 603139's Return on Equity is forecast to be high in 3 years time


Discover growth companies